- CareView posted a net loss of about $3.2 million for fiscal 2025.
- Revenue rose to about $9 million, driven by higher recurring software revenue.
- Operating loss narrowed to about $55,000 as operating expenses fell about 8% to about $9.1 million.
- Cash, cash equivalents and restricted cash ended period at about $1.5 million, while working capital deficit stood at about $43.5 million.
- CareView extended maturity of its credit agreement with PDL BioPharma to June 30, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareView Communications Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-010356), on March 30, 2026, and is solely responsible for the information contained therein.
Comments